PMA device
Belotero Balance Dermal Filler
Merz North America, Inc. · Implant, Dermal, For Aesthetic Use (LMH, Class III) · First FDA decision Nov 14, 2011, newest May 3, 2026Aesthetic skin, fat and body contouring
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
9
PMA pathway
Device trials
772
Naming "Belotero Balance"
MAUDE reports
292
Brand "Belotero Balance", since 2015
PubMed studies
39
Mentioning "Belotero Balance"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Belotero Balance Dermal Filler
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 9 decisions filed under this name.
P090016-S067 · Decided May 3, 2026 · 249 days after receipt · Normal 180 Day Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
5 more FDA decisions with a free account
Older decisions: P090016-S003, P090016-S001, P090016
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Belotero Balance", any status and sponsor, newest update first.
i+Med S.Coop.Not on our public-company list
NCT07402395 · 40 participants · Start Nov 22, 2024 · Primary completion Sep 2, 2025
Device: BtHIntimate® Injectable Hyaluronic Acid Treatment · For: Vulvar Atrophy
Sites: Madrid, Spain
771 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Belotero Balance", and for the whole product code for context.
This brand
292 reports: 0 malfunction, 291 injury, 0 death
Whole product code LMH
16,542 reports: 1,388 malfunction, 15,105 injury, 12 death
Newest reports for this brand
3013840437-2026-00141 · Received Oct 8, 2026 · Event dated Oct 1, 2026
Device type: Implant, Dermal, For Aesthetic Use (LMH)
Device problem as coded: Off-Label Use; Improper or Incorrect Procedure or Method; Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Obstruction/Occlusion; No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Belotero Balance"[tiab]. The summary above synthesizes these.
- Review of key Belotero Balance safety and efficacy trials.
Lorenc ZP, Fagien S, Flynn TC, et al. · Plast Reconstr Surg · 2013Review
- Response of 21 Hyaluronic Acid Fillers to Recombinant Human Hyaluronidase.
Park KE, Mehta P, Kherani F, et al. · Plast Reconstr Surg Glob Open · 2023
- Soft tissue distribution pattern of facial soft tissue fillers with different viscoelastic properties.
Rosamilia G, Hamade H, Freytag DL, et al. · J Cosmet Dermatol · 2020
- A Prospective, Multicenter, Evaluator-Blind, Randomized, Controlled Study of Belotero Balance (+), a Hyaluronic Acid Filler With Lidocaine, for Correction of Infraorbital Hollowing in Adults.
Biesman BS, Montes JR, Radusky RC, et al. · Aesthet Surg J · 2024Randomized Controlled Trial, Multicenter Study
- Granulomatous reaction to Belotero Balance: A case study.
Gandy J, Bierman D, Zachary C · J Cosmet Laser Ther · 2017Case Reports
- Cohesive Polydensified Matrix Hyaluronic Acid for Fine Lines.
Sundaram H, Fagien S · Plast Reconstr Surg · 2015Review
- Treating Sunken Upper Eyelid With Hyaluronic Acid: Recommendations and Results.
Spada J · J Drugs Dermatol · 2022
- Molecular weight analyses and enzymatic degradation profiles of the soft-tissue fillers Belotero Balance, Restylane, and Juvéderm Ultra.
Flynn TC, Thompson DH, Hyun SH · Plast Reconstr Surg · 2013
- Hyaluronic acid gel distribution pattern in periocular area with high-resolution ultrasound imaging.
Goh AS, Kohn JC, Rootman DB, et al. · Aesthet Surg J · 2014Research Support, Non-U.S. Gov't
- How Much Does Filler Apparatus Influence Ease of Injection (and Hence, Potential Safety)?
Ginter A, Lee T, Woodward J · Ophthalmic Plast Reconstr Surg · 2023
- Long-Term Effects of Tear Trough Hyaluronic Acid Filler: A Retrospective Study.
Puyana C, Montes JR · J Clin Aesthet Dermatol · 2025
- Hyaluronic Acid Fillers: Science and Clinical Uses.
Gutowski KA · Clin Plast Surg · 2016Review
Other devices of this type
Also filed under product code LMH.
- RADIESSE® Injectable ImplantMerz North America, Inc. · PMA 2026
- SculptraQ-Med AB · PMA 2024
- Restylane Injectable GelQ-Med AB · PMA 2022
- Restylane® ContourQ-Med AB · PMA 2026
- Juvederm Voluma XCAllergan · PMA 2025
- Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, SkinviveAllergan · PMA 2026
- Restylane® Lyft with LidocaineQ-Med AB · PMA 2025
- Belotero Balance (+) Lidocaine Dermal FillerMerz North America, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.